I-SPY 2.2 study finds early breast cancer patients may benefit from pre-surgery combination of antibody drug conjugate Dato-DXd and checkpoint inhibitor durvalumab.
UCSF Clinical and Life Sciences Building will bring research, innovation, primary and specialty care clinics, and world-class cancer therapy to San Francisco’s central waterfront.
Prostate cancer screenings among Black men have tripled at some SF health providers as part of this UCSF-City of San Francisco project that’s paving the way for state-wide changes.
Therapies for the K-Ras oncogene inspire a new way to target the GTPases, a family of enzymes whose dysfunction can lead to Parkinson’s and many other diseases.
Researchers will investigate aggressive prostate cancer from a mechanistic, biomarker and therapeutic perspective, with a goal of accelerating clinical innovation through translational research.
UCSF’s Mekhail Anwar wins up to $15 million from ARPA-H to develop a next-generation miniature scanner powerful enough to detect individual cancer cells during surgery.
